Dec 15, 2025 7:30 am EST Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer
Dec 11, 2025 7:30 am EST Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in Texas
Dec 8, 2025 7:30 am EST Abeona Therapeutics® Announces First Patient Treatment with ZEVASKYN® Gene Therapy
Dec 1, 2025 7:30 am EST Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 12, 2025 7:30 am EST Abeona Therapeutics® Reports Third Quarter 2025 Financial Results and Corporate Updates
Nov 7, 2025 7:30 am EST Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
Nov 3, 2025 7:30 am EST Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 30, 2025 10:45 am EDT Abeona Therapeutics® Announces Permanent J-Code for ZEVASKYN® (prademagene zamikeracel)
Oct 20, 2025 8:30 am EDT Abeona Therapeutics® Appoints James A. Gow, MD, MBA, MS, MHCM, as Senior Vice President, Head of Clinical Development & Medical Affairs
Oct 13, 2025 7:30 am EDT Abeona Therapeutics® Announces ABO-503 Gene Therapy for X-linked Retinoschisis (XLRS) Selected by FDA for Rare Disease Endpoint Advancement (RDEA) Pilot Program
